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Abstract
Background: Cancer cells utilize a variety of mechanisms to evade immune detection and attack. Effective
immune detection largely relies on the formation of an immune synapse which requires close contact between
immune cells and their targets. Here, we show that MUC16, a heavily glycosylated 3-5 million Da mucin expressed
on the surface of ovarian tumor cells, inhibits the formation of immune synapses between NK cells and ovarian
tumor targets. Our results indicate that MUC16-mediated inhibition of immune synapse formation is an effective
mechanism employed by ovarian tumors to evade immune recognition.
Results: Expression of low levels of MUC16 strongly correlated with an increased number of conjugates and
activating immune synapses between ovarian tumor cells and primary naïve NK cells. MUC16-knockdown ovarian
tumor cells were more susceptible to lysis by primary NK cells than MUC16 expressing controls. This increased lysis
was not due to differences in the expression levels of the ligands for the activating receptors DNAM-1 and NKG2D.
The NK cell leukemia cell line (NKL), which does not express KIRs but are positive for DNAM-1 and NKG2D, also
conjugated and lysed MUC16-knockdown cells more efficiently than MUC16 expressing controls. Tumor cells that
survived the NKL challenge expressed higher levels of MUC16 indicating selective lysis of MUC16
low targets. The
higher csMUC16 levels on the NKL resistant tumor cells correlated with more protection from lysis as compared to
target cells that were never exposed to the effectors.
Conclusion: MUC16, a carrier of the tumor marker CA125, has previously been shown to facilitate ovarian tumor
metastasis and inhibits NK cell mediated lysis of tumor targets. Our data now demonstrates that MUC16 expressing
ovarian cancer cells are protected from recognition by NK cells. The immune protection provided by MUC16 may
lead to selective survival of ovarian cancer cells that are more efficient in metastasizing within the peritoneal cavity
and also at overcoming anti-tumor innate immune responses.
Introduction
Ovarian cancer is the deadliest of the gynecological
malignancies. Eighty percent of the 14,000 cases of ovar-
ian cancer that are diagnosed each year are of epithelial
cell origin. Epithelial ovarian cancer is associated with
the formation of a large amount of peritoneal fluid and
is extremely metastatic. Immune regulation plays an
important role in controlling ovarian tumor growth.
Infiltration of T cells within the tumor is strongly
associated with an increase in 5-year survival of ovarian
cancer patients [1]. Primary cancer cells are known to
express PVR and nectin, ligands for the activating NK
cell receptor DNAM-1 [2,3]. Recognition of these
ligands results in lysis of ovarian cancer cells by naïve
NK cells present in the systemic circulation.
Ovarian tumors, however, have developed elaborate
mechanisms to counter immune recognition and attack.
Factors produced by the tumor can alter the expression
of important activating molecules on immune cells pre-
sent in the peritoneal cavity. In one study, a 10-14 kDa
protein produced by the tumor cells was shown to
downregulate the expression of the key signaling
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causes impairment of the immune response [4,5].
Macrophage migration inhibitory factor (MIF) produced
by ovarian tumor cells decreases the transcription and
expression of the activating receptor NKG2D on NK
cells thereby inhibiting their ability to recognize and lyse
ovarian tumor targets [6]. Other NKG2D ligands
expressed by ovarian cancer cells include MICA, MICB,
and Letal [7-9].
We have studied the effects of one particular factor
produced in high quantities by the tumor cells, MUC16,
and its effect on the cytolytic function of human NK
cells [10,11]. MUC16 is a membrane spanning mucin
with an average molecular weight between 3-5 million
Da [12]. The high molecular weight of MUC16 is a
result of the over 24,000 amino acids that constitute the
protein backbone and also the extensive O-linked and
N-linked glycosylation of this molecule [12-14]. Ovarian
tumors present MUC16 as a Type I membrane glyco-
protein on their cell surface. We refer to the cell surface
bound mucin as csMUC16. Proteolytic cleavage at a site
50 amino acids upstream of the transmembrane region
is hypothesized to result in shedding of the mucin from
ovarian tumors [12,15,16]. The shed mucin, sMUC16, is
present at considerable concentration (5-20 nM) in the
peritoneal fluid and also leaks into the systemic circula-
tion. csMUC16 and sMUC16 carry a repeating peptide
epitope that has been previously characterized as the
ovarian tumor marker CA125 [13,17].
sMUC16 is a potent inhibitor of the cytolytic ability of
NK cells [11]. Incubation of NK cells from healthy
donors with sMUC16 results in a 40-70% decrease in
surface expression of CD16 [10,11]. Downregulation of
CD16, a low affinity Fc receptor, impairs the ability of
the peritoneal NK cells to mediate Antibody-Dependent
Cell Mediated Cytotoxicity (ADCC) [5,18-22]. Thus
sMUC16 directly inhibits the natural cytotoxicity
mechanism of NK cells and may also indirectly attenu-
ate ADCC in NK cells of ovarian cancer patients.
To date, csMUC16 has not been studied for its poten-
tial role in protecting ovarian tumor cells from immune
attack. csMUC16, similar to sMUC16, may directly
interact with NK cells and inhibit their ability to lyse
tumor targets. Alternatively, csMUC16 may also protect
ovarian tumor cells from NK attack by a different
mechanism. Mucins are known to possess both adhesive
and anti-adhesive properties [23]. csMUC16 acts as an
anti-adhesive molecule in the endometrium and must be
absent for successful trophoblast adherence to the endo-
metrial wall [24]. MUC16 has also been shown to have
a barrier function against pathogen adherence on cor-
neal epithelial cell layers [25-27]. RNA interference of
MUC16 expression in human corneal-limbal epithelial
cells resulted in increased Staphylococcus aureus adhe-
sion on the corneal epithelial cell layer [25].
Because NK cells form immune synapses with their
target cells [28-30], which involve very close cell-cell
contact, the presence of an anti-adhesive molecule on
the surface of ovarian tumor cells may have significant
consequences for tumor cell interactions with NK cells.
The formation of these synapses allows NK cells to
effectively read the inhibitory or activating ligands on
the surface of the target cells. The strength and level of
expression of these ligands determines the subsequent
action of the NK cell [31]. The inability of NK cells to
form these synapses would restrict effector cell activa-
tion and subsequent lysis of tumor targets.
Here, we provide evidence that the expression of
csMUC16 attenuates the interactions between ovarian
cancer cells and NK cells. Our data indicates that NK
cells are unable to form immune synapses with the
ovarian tumor targets, regardless of the expression of
activating or inhibitory ligands on the surface of the
tumor cells. This results in another redundant molecular
mechanism that epithelial ovarian tumor cells utilize to
avoid immune attack.
Results
NK cells preferentially target csMUC16
low OVCAR-3 cells
OVCAR-3 is an established ovarian tumor cell line that
expresses csMUC16 and releases sMUC16 into the cul-
ture media. This cell line was also used for the cloning
of MUC16 [17]. This cell line is therefore a good model
to study the function of sMUC16 and csMUC16 [32].
NK cells derived from peripheral blood of healthy
donors are unable to efficiently lyse OVCAR-3 cells
[33,34]. To determine the role of csMUC16 in immune
protection we conducted confocal microscopy experi-
ments to analyze the direct interactions between
OVCAR-3 cells and NK cells. The OVCAR-3 cell popu-
lation exhibits a wide range of csMUC16 expression as
determined by flow cytometry [35]. We developed an
arbitrary scale to categorize OVCAR-3 as csMUC16
low,
csMUC16
medium, and csMUC16
high based on fluorescent
intensity as visualized by microscopy (Figure 1A).
OVCAR-3 cells were incubated with NK cells derived
from peripheral blood of healthy donors. Invariably, we
observed that NK cells selectively conjugated with
csMUC16
low OVCAR-3 cells as compared to csMUC16-
medium and csMUC16
high cells (Figure 1A, B). Quantifi-
cation of NK cell-OVCAR-3 conjugates clearly showed
that the effector cells formed 6-7-fold more conjugates
with csMUC16
low OVCAR-3 cells compared to csMU-
C16
high OVCAR-3 (Figure 1C). Intermediate numbers of
conjugates were observed between NK cells and
OVCAR-3 cells expressing medium levels of csMUC16.
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low cells express comparable levels of DNAM-1
and NKG2D ligands
One potential reason for differential binding between
NK cells and csMUC16 low or high expressing
OVCAR-3 cells could be that the csMUC16
low cells
were expressing higher levels of ligands of the activating
receptors DNAM-1 and NKG2D that have been shown
to play an important role in lysing primary ovarian can-
cer cells [2,8,9,36]. To test this hypothesis, expression of
DNAM-1 and NKG2D ligands on the OVCAR-3 cells
was examined in relation to csMUC16 levels.
DNAM-1-Fc or NKG2D-Fc chimeras were added to
OVCAR-3 cells and the cells were gated for high or low
csMUC16 expression (Figure 2). OVCAR-3 cells expres-
sing low or high csMUC16 expressed comparable levels
of DNAM-1 and NKG2D ligands (Figure 2). These data
indicate that differences in expression of DNAM-1 or
NKG2D ligands was not a factor in the ability of NK
cells to conjugate to OVCAR-3 cells.
MUC16 knock-down OVCAR-3 cells
The significantly reduced ability of NK cells to bind to
csMUC16
high OVCAR-3 cells suggested a potential role
for this mucin in protecting ovarian cancer cells from
immune recognition. To investigate this immuno-
protective role, we employed MUC16 knock-down cells
that were successfully utilized in our recent studies
[35,37]. The subline csMUC16
neg-OVC expresses an
endoplasmic reticulum localized scFv fragment of the
anti-MUC16 antibody VK-8 that prevents expression of
csMUC16 and sMUC16. A control subline designated
csMUC16
pos-OVC that expresses an scFv fragment of
an irrelevant murine IgG has no effect on the expression
of csMUC16 and sMUC16 [37]. Expression of csMUC16
on both sublines is shown in Figure 3. The scFv-
MUC16 complex is rapidly degraded in the proteasomes
and the mucin does not accumulate in the cytoplasm of
the tumor cells (see additional file 1). The csMUC16
pos-
OVC and csMUC16
neg-OVC were negative for MUC4
expression and did not exhibit any major difference in
the levels of MUC1 (Figure 3). This is important to note
as it has previously been shown that both MUC1 and
MUC4 exert anti-adhesive effects on immune synapse
formation [38,39].
Expression of DNAM-1 and NKG2D ligands and HLA class
I on csMUC16
pos-OVC and csMUC16
neg-OVC
NKG2D and DNAM-1 ligand expression and presenta-
tion of HLA class I antigens on tumor cells are impor-
tant factors that determine activation or inhibition of
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Figure 1 Selective targeting of csMUC16
low OVCAR-3 cells by NK cells. A, Upper panels show the classification of csMUC16
low, medium, and
high OVCAR-3 cells. This classification was used to determine NK cell conjugation with different subsets of OVCAR-3 cells. The lower panel shows
the corresponding bright field image of the cell in the upper panel. B, The upper panel is a 60× view of NK cells (white arrows) forming
conjugates with csMUC16
low cells. NK cells surrounding csMUC16
high cells are not touching the tumor cell. The lower panel is a digital zoom
image demonstrating selective conjugation of NK cells (white arrow) with csMUC16
low and not with csMUC16
high OVCAR-3 cells (red arrows). C,
Conjugates of NK cells with low, medium and high csMUC16 expressing cells were quantified by averaging the number of conjugates observed
per 50 fields. Data shown is mean of four independent experiments performed with NK cells from separate donors. A one-way ANOVA was
performed and the resulting p value = .0015.
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neg-OVC and csMUC16
pos-OVC
express comparable levels of DNAM-1 and NKG2D
ligands, as determined by monitoring the binding of
DNAM-1-Fc and NKG2D-Fc chimeras to these two sub-
lines (Figure 3). Similarly comparable levels of MHC
class I antigens were expressed by csMUC16
neg-OVC
and csMUC16
pos-OVC (Figure 3).
csMUC16 protects csMUC16
pos-OVC from NK cell lysis
HLA class I antigens serve as strong inhibitory ligands of
the Killer Immunoglobulin-like Receptors (KIR) of NK
cells. Therefore, HLA class I expression protects tumor
cells from NK cell attack. However, although comparable
levels of HLA class I were expressed on the csMUC16
pos-
OVC and csMUC16
neg-OVC the sublines exhibited dif-
ferential susceptibility to NK cell mediated lysis. Higher
protection of the csMUC16
pos-OVC from NK cell
mediated cytolysis as compared to the csMUC16
neg-OVC
was consistently observed (Figure 4). NK cells used in
these assays were obtained from the peripheral blood of
four healthy donors. Cytotoxicity assays at 10:1, 5:1 and
1:1 effector cell:target cell ratios showed that the
csMUC16
neg- O V Cw e r el y s e da tas i g n i f i c a n t l yh i g h e r
level than the csMUC16
pos-OVC (Figure 4).
NKL cells lack KIR expression and are more effective at
killing csMUC16
neg-OVC
As shown in Figure 3, both the csMUC16
pos-OVC and
csMUC16
neg-OVC expressed HLA class I antigens that
could contribute to their protection from NK cell
mediated lysis. Therefore, another effector cell model
was required where the protection provided by HLA
class I antigens would not be as pronounced as with the
primary NK cells from healthy donors.
The NK cell leukemia cell line, NKL, does not express
the prominent KIR (Killer Immunoglobulin-like Recep-
tors) CD158a, CD158b, and CD158e (Figure 5A). These
KIRs are inhibitory receptors that bind to HLA class I
molecules and abrogate the cytotoxic responses of NK
cells [40]. The lack of KIR on NKL cells therefore
reduces the inhibitory effect arising out of a major path-
way (HLA class I-KIR) displayed by the csMUC16
pos-
OVC and csMUC16
neg-OVC sublines and allows better
isolation of the immunoprotective properties of
csMUC16.
To assess the ability of NKL cells to lyse either sub-
line, flow cytometry based cytotoxicity assays were per-
formed with these cells. There was a 2-3 fold increase in
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Figure 2 DNAM-1 and NKG2D ligand expression is comparable on csMUC16
high expressing OVCAR-3 cells. OVCAR-3 cells were stained
for csMUC16 expression, and then NKG2D-Fc or DNAM-1-Fc and an appropriate secondary antibody were added. Cells were initially gated on
live single events of tumor cells that were csMUC16
low or csMUC16
high. The binding of NKG2D-Fc or DNAM-1 to gated csMUC16
low (gray line)
and csMUC16
high (black line) is shown in histogram form. Data is representative of three independent experiments.
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Figure 3 Expression of mucins and NK cell activating and inhibitory molecules on csMUC16
neg-OVC and csMUC16
pos-OVC.M U C 1
expression on both sublines is similar and MUC4 expression is absent. Expression of DNAM-1 and NKG2D ligands on the sublines was
determined by staining with Fc chimeras (15 μg/mL) of these two receptors followed by labeling with fluorophore conjugated anti-Fc secondary
antibody. HLA class I expression on the sublines was determined by labeling with FITC conjugated w6/32. Histograms of live single events are
shown in all plots. Data is representative of three independent experiments. Shaded peaks show control cells incubated with only the
fluorescently-tagged secondary antibodies. Un-shaded histograms are for cells incubated with the primary antibodies or Fc chimeras and the
fluorescently labeled secondary antibodies.
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Page 5 of 14killing when NKLs were paired with csMUC16
neg-OVC
compared to csMUC16
pos-OVC (Figure 5B).
csMUC16
pos-OVC form low numbers of conjugates with
NK and NKL cells
Because NK cells were selectively binding to csMU-
C16
low OVCAR-3 cells (Figure 1), we determined if they
also exhibited a higher ability to conjugate with
csMUC16
neg-OVC. We first quantified doublet forma-
tion between fluorescently tagged effector and target
cells by flow cytometry. Approximately 1.5-fold more
doublets were observed between NK cells (isolated from
three different healthy donors) and csMUC16
neg-OVC
as compared to csMUC16
pos-OVC (Figure 6A).
Similar to our observations with NK cells, we were able
to demonstrate that csMUC16
neg-OVC formed increased
numbers of conjugates in plate-based adhesion assays with
NKL cells compared to csMUC16
pos-OVC (Figure 6B).
Higher adhesion correlated with 2-3-fold higher killing of
the csMUC16
neg-OVC by the NKL cells (Figure 5B).
csMUC16
neg-OVC cells formed higher numbers of
activating immune synapses with NK cells
Conjugation between NK cells and targets results in for-
mation of immune synapses. NK cells form activating
immune synapses in order to lyse target cells. We
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Figure 4 csMUC16 protects ovarian cancer cells from lysis by
NK cells. NK cells from four healthy donors were isolated and
51Cr
release lysis assays at 10:1, 5:1, and 1:1 effector:target ratios were
conducted using csMUC16
neg-OVC and csMUC16
pos-OVC cells.
Chromium release from the targets was determined after 4 h
incubation under standard tissue culture conditions. Percent lysis
was calculated by determining the spontaneous and maximum
release of radioactivity from each cell line.
Figure 5 NKLs lack KIRs and exhibit reduced ability to lyse csMUC16
pos-OVC. A Expression of KIR on NKL cells was determined by flow
cytometry. B. Flow cytometry based cell lysis assays (24:1 effector:target ratio) were conducted to demonstrate that NKL cells lyse csMUC16
neg-
OVC cells to a greater extent than the csMUC16
pos-OVC cells. Mean, standard deviation and p-value of three independent measurements is
shown.
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Page 6 of 14therefore determined if the increased conjugation between
csMUC16
neg-OVC and NK cells resulted in the formation
of activating immune synapses. Activating immune
synapses between NK cells and csMUC16
pos-OVC and
csMUC16
neg-OVC were quantified by determining the
polarization of LFA-1 or CD2 and F-actin at the interface
between the effector and target cells. csMUC16
neg-OVC
cells formed twice as many activating immune synapses
with NK cells compared to csMUC16
pos-OVC (Figure 7).
In some cases, multiple NK cells were also found to form
simultaneous activating immune synapses with the
csMUC16
neg-OVC cells (Figure 7B). Although NK cells
were found in the vicinity of csMUC16
pos-OVC, activating
immune synapses were not formed (Figure 7B).
csMUC16 protects adherent tumor cells from NKL-
mediated lysis
The ability of NKL cells to selectively lyse csMUC16
neg-
OVC and csMUC16
pos-OVC was further evaluated in
co-culture experiments. An additional MUC16-knock-
down clone (csMUC16
neg-OVC-A) was also used in
these experiments. This protocol for the generation of
this additional cell line has been reported [37]. The
three sublines were plated at equal densities in separate
wells. After cells were 70% confluent, NKL cells were
introduced in the cultures and plates were incubated for
24 h (Figure 8A) or 48 h (Figure 8B). At the end of the
incubation, NKL cells and lysed non-adherent ovarian
tumor cells were removed and the remaining adherent
colonies and individual cells were manually counted.
Very few adherent colonies and cells per observed field
remained in the csMUC16
neg-OVC/NKL and csMUC16-
neg-OVC-A/NKL co-cultures (Figure 8). However, 3-4-
fold more colonies and cells/field were detected in the
csMUC16
pos-OVC/NKL co-cultures (Figure 8).
NKL-resistant csMUC16
pos-OVC express higher levels of
csMUC16
Adherent csMUC16
pos-OVC cells that were resistant to
two sequential NKL challenges (Figure 8) were desig-
nated as csMUC16
pos-OVC-R. The surviving csMUC16-
pos-OVC-R cells were further cultured to 100%
confluence and csMUC16 expression on these cells was
determined by flow cytometry. Compared to csMUC16-
pos-OVC that were cultured at identical confluence and
similar passage number, but had not been exposed to
NKL cells, the csMUC16
pos-OVC-R expressed 2-fold
higher levels of csMUC16 (Figure 9A).
Based on all of the data obtained in this study we pre-
dicted that the csMUC16
pos-OVC-R would be more
resistant to killing by effector cells due to the even
higher expression of csMUC16. Indeed, when NKL cells
were used as effector cells, the csMUC16
pos-OVC-R
cells showed a 3-4-fold decreased susceptibility to lysis
as compared to the csMUC16
pos-OVC that had not
been previously subjected to NKL treatment (Figure 9B).
These data are consistent with results obtained from the
cytotoxicity experiments using csMUC16
pos-OVC and
csMUC16
neg-OVC and also support our initial observa-
tion that NK cells selectively form decreased numbers of
conjugates with OVCAR-3 cells that express higher
levels of csMUC16.
Discussion
An NK cell lyses target cells based on the expression
level and strength of activating and inhibitory signals.
Expression of HLA class I antigens on ovarian tumor
cells acts as a strong signal that abrogates the cytotoxic
responses of NK cells by serving as ligands for the inhi-
b i t o r yK I Ra n dL I Rr e c e p t o r s .I na d d i t i o n ,s i g n a l
B
csMUC16pos-OVC
csMUC16neg-OVC
0
1000
2000
3000
4000
5000
F
l
u
o
r
e
s
c
e
n
c
e
50K NKL 100K NKL
p=0.05
p=0.04
#7 #12
0
25
50
75
%
 
H
e
t
e
r
o
t
y
p
i
c
 
C
o
n
j
u
g
a
t
e
 
F
o
r
m
a
t
i
o
n
p=0.02
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A
Figure 6 csMUC16
neg-OVC form more conjugates with NK and
NKL cells than csMUC16
pos-OVC. A, NK cells from healthy donors
were labeled with CellTracker Green and mixed with CellTracker
Blue labeled csMUC16
neg-OVC or csMUC16
pos-OVC cells.
Conjugation between the tumor cells and NK cells was determined
by flow cytometry. Mean values of NK cell-tumor cell conjugation
obtained from experiments conducted with three healthy donors
are shown. B. csMUC16
neg-OVC or csMUC16
pos-OVC were plated in a
96-well plate and allowed to grow to 70-80% confluence. Calcein
dyed NKLs were added to the plate. After incubation, non-adherent
cells were removed by washing and the NKL cells bound to tumor
targets were quantified using a fluorescence plate reader. Data for
two experiments was combined for a total of 12 replicates.
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Page 7 of 14peptides of HLA class I antigens bind to the non-poly-
morphic HLA-E molecules [41]. The signal peptide-
HLA-E complex is presented on the cell surface where
it serves as a ligand for the inhibitory CD94/NKG2A
receptor complex expressed on NK and other immune
cells [42-44]. On the other hand, ovarian tumor cells
also express ligands for the activating receptors NKG2D
and DNAM-1 [2] that make them susceptible to NK cell
mediated lysis.
Recognition of inhibitory or activating ligands requires
NK cells to form close contacts with tumor cells. The
formation of such cell-cell interactions is dependent
upon the molecular landscape of the cell surface on
both cell types. While adhesive molecules are required
to formalize contacts between the cancer and effector
cells, anti-adhesive molecules may hinder proper recog-
nition of the tumors by NK cells. This study identifies
csMUC16 as an inhibitor of NK cell/tumor cell contact
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Figure 7 csMUC16 inhibits NK activating synapse formation. A. NK cells from healthy donors were mixed with csMUC16
neg-OVC and
csMUC16
pos-OVC cells and confocal microscopy was conducted using 10× magnification. White arrows indicate NK cells bound to tumor cells
and some forming activating immune synapses. B. Immune synapses between the NK cells and csMUC16
neg-OVC at 40× magnification are
shown. NK cells are present in the vicinity of csMUC16
pos-OVC cells but form significantly less conjugates and immune synapses. C. Immune
synapses between NK cells from three healthy donors and the csMUC16
neg-OVC or the csMUC16
pos-OVC cells were quantified by counting
conjugates that showed polarization of LFA-1 and CD2 divided by the total number of conjugates (defined as two cells in contact).
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to evade immune recognition.
NK cells isolated from peripheral blood of healthy
donors preferentially form conjugates with OVCAR-3
cells that expressed lower levels of csMUC16 (Figure 1).
We determined that the high degree of targeting of the
csMUC16
low OVCAR-3 cells was not due to higher
expression of NKG2D or DNAM-1 ligands. The role of
csMUC16 in attenuating NK cell recognition of ovarian
cancer cells was delineated by using the csMUC16
knockdown OVCAR-3 subline, csMUC16
neg-OVC. The
csMUC16
neg-OVC and the matching control subline
csMUC16
pos-OVC are similar in their expression of
NKG2D and DNAM-1 ligands. HLA class I levels were
slightly elevated on csMUC16
neg-OVC cells compared
to csMUC16
pos-OVC. These observations would suggest
that csMUC16
neg-OVC would be better protected from
NK cell killing as compared to csMUC16
pos-OVC. To
the contrary, primary NK cells lyse the csMUC16
neg-
OVC to a significantly greater extent than the
csMUC16
pos-OVC. Similar effect was observed when the
KIR
neg NKL cells were used as effectors. Because of the
lack of KIR, the expression of HLA class I on the targets
has a markedly reduced inhibitory effect on the cytolytic
capacity of the NKL cells. Therefore, lower amount of
lysis of the csMUC16
pos-OVC observed in the NKL
experiments is primarily due to the protection provided
by csMUC16.
We have shown previously that sMUC16 binds specifi-
cally to a subset of NK cells in epithelial ovarian cancer
patients. Our current data indicates that the receptor for
sMUC16 is the inhibitory receptor Siglec-9 (Belisle et al
manuscript in preparation). The binding of csMUC16 to
Siglec-9 could be a mechanism by which csMUC16 is
causing inhibition of NK cells. We have shown using
cytotoxicity assays that NKL cells are also inhibited by
MUC16 present on csMUC16
pos-OVC cells. This is sig-
nificant because NKLs are Siglec-9 negative and do not
bind to sMUC16 (data not shown), indicating Siglec-9-
c s M U C 1 6b i n d i n gm a yn o tp l a yar o l ei nt h eo b s e r v e d
inhibition of cytotoxicity.
An alternate explanation for NK cell protection
afforded by csMUC16 lies in the extraordinary biochem-
ical properties of the molecule itself. Mucins are known
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Figure 8 csMUC16 shields ovarian cancer cells from NKL mediated lysis. A. NKL cells were added to confluent cultures of csMUC16
neg-OVC
or csMUC16
pos-OVC cells at a 1:1 effector:target ratio. After incubation for A, 24 h and B, 48 h the number of adherent colonies and adherent
cells surviving the NKL challenge were counted by microscopic examination of five random fields. This experiment was repeated in triplicate and
mean values (n = 15 fields) and standard deviation are shown.
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Page 9 of 14to exhibit both adhesive and anti-adhesive properties. In
cancer, the loss of apical expression of these large mole-
cules and the subsequent distribution over the entire
cell membrane has consequences for cell-cell interac-
tions [45]. The large size of the molecules as well as the
extensive O-glycosylation present on mucins contributes
to their anti-adhesive properties. MUC16 contains a
large number of core 2 type O-glycans [14]. The overex-
pression of core 2 type O-glycans on T cells has been
implicated in disrupting cell-cell interactions between B
and T cells, preventing cross-talk between the cells and
impairing the humoral immune response [46].
MUC16 has a protein backbone of approximately
24,000 amino acids [12] and a high degree of glycosyla-
tion, indicating that it may extend a considerable dis-
tance out from the surface of the cell. Mucins such as
MUC1, MUC4 and MUC16 have semi-flexible rod-like
structures extending outwards from the cell surface
[45,47]. It is estimated that a 28-mer peptide with O-
glycan chains has a linear length of approximately 7 nm
[47]. Based on these calculations, csMUC16, with an
approximately 24,000 amino acid protein backbone, can
be expected to extend up to 1-5 μm from the surface of
ovarian tumor cells. The NK synaptic cleft requires
apposition of the effector and the target cells over a dis-
tance of 10-55 nm [48]. Thus, ovarian cancer cells may
specifically utilize the very large and heavily glycosylated
csMUC16 molecule to prevent the conjugation and
eventual binding to NK cells.
Other large molecules have been shown to interfere
with cell-cell contact because of the bulky nature of
their extracellular domains. CD43, which is abundantly
expressed on T cells and is heavily glycosylated, is
removed from the immune synapse before synapse for-
mation between T cells and APCs [49]. Other research-
ers have shown that dendritic cells induce the
polarization of MUC1 on T cells to sites opposing the T
cell-dendritic cell interface [39]. Carraway and collea-
gues have conclusively demonstrated that MUC4,
another large molecular weight mucin, shields cancer
cells from lysis by the lymphokine activated killer cells
due to its anti-adhesive properties [38]. As the expres-
sion of both MUC1 and MUC4 were similar on
csMUC16
pos-OVC and csMUC16
neg-OVC, these mucins
did not contribute to the differences in conjugation and
lysis that were seen between these two sublines.
T h et a r g e t i n go ft h ec s M U C 1 6
low ovarian tumor cells
by NK cells may result in the selective survival of csMU-
C16
high cancer cells. Such a selective increase in csMU-
C16
high ovarian cancer cells is supported by our
observation that csMUC16
pos-OVC that were resistant
to NKL attack expressed a higher level of csMUC16
(Figure 9A). Higher expression of csMUC16 on the sur-
viving cancer cells may not only allow them to
withstand NK cell killing, as demonstrated in Figure 9B,
but also provide them an avenue to do so while expres-
sing lower levels of HLA and thereby reducing their vul-
nerability to T cells.
Our data may represent an example of an immunoe-
diting mechanism that allows progression and prolifera-
tion of ovarian tumors. NK cells may selectively
eliminate csMUC16
low cells. The csMUC16
high cells sur-
viving NK cell attack not only have the advantage of
effectively evading immune attack but can also utilize
csMUC16 to adhere to mesothelial cells at various sites
within the peritoneal cavity [35]. The surviving csMU-
C16
high ovarian tumor cells may also be expected to
shed higher amounts of sMUC16. We have now demon-
strated that sMUC16 binds Siglec-9, an inhibitory recep-
tor present on cytolytic NK cells in addition to subsets
of B cells and a majority of monocytes (Belisle et al
manuscript in preparation). Selective immunoediting of
csMUC16
high ovarian tumors may therefore lead to
tumors that have a higher potential to withstand
immune attack and also to metastasize and proliferate
in the peritoneal environment.
Conclusion
We have conclusively shown that the expression of
csMUC16 blocks the conjugation step of immune
synapse formation of NK cells with ovarian cancer tar-
gets. This blockage prevents NK cell lysis of cancer
cells. Immune protection afforded by csMUC16 should
therefore be considered as another important mechan-
ism that promotes tumor growth.
Materials and methods
Reagents and effector cell isolation
Unless otherwise stated, all chemicals were purchased
from either Sigma or Fisher. NK cells were isolated
from healthy donors using the RosetteSep (Stem Cell
Technologies) NK Cell Isolation Kit protocol. Purity of
the isolated NK cells was between 80 and 90% based on
flow cytometry using anti-CD3, CD16, and CD56 anti-
bodies. Antibodies against MUC1, CD2, CD3, CD16,
CD56, CD158a, CD158b, CD158e, and HLA Class I
(w6/32), were from BD Biosciences. Anti-LFA-1 and
anti-MUC4 antibodies were from eBiosciences and
Zymed Laboratories, respectively. OVCAR-3 cells were
obtained from ATCC (Rockville, Maryland). OVCAR-3
csMUC16 knockdown sublines csMUC16
neg-OVC and
csMUC16
neg-OVC-A and control subline csMUC16
pos-
OVC were obtained as described in our recent studies
[37,35].
Slide preparation and analysis for confocal microscopy
NK-target synapse experiments were conducted accord-
ing to previously established protocols [30,50,51].
OVCAR-3, csMUC16
pos-OVC, and csMUC16
neg-OVC
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OVCAR-3 cells by ATCC. Target cells (7.5 × 10
4 cells)
were mixed with NK cells at a 1:1 ratio in a total
volume of 400 μl. The cells were centrifuged for 5 min-
utes at 100 × g and I incubated at 37°C at 5% CO2 for
25 minutes. The media was aspirated and cells were
resuspended in PBS without calcium and magnesium
and placed on poly-L-lysine coated coverslips. All subse-
quent procedures were performed at room temperature.
Cells were fixed with 3% paraformaldehyde (Poly-
sciences, Inc.) for 15 min, washed twice with 150 mM
glycine, permeabilized with 0.1% Triton-X for 4 min,
washed with PBS, and blocked overnight with PBS con-
taining 5% goat serum.
Cells were stained with murine antibodies against
LFA-1, CD2, or MUC16 (VK8 antibody kindly provided
by Dr. Beatrice Yin) in 5% goat serum for 30 min. Cov-
erslips were washed with 1 mL PBS, stained with a
cocktail of goat anti-mouse FITC (Jackson
ImmunoResearch), and rhodamine conjugated phalloidin
(Invitrogen) for 30 min. Cells were washed with PBS,
dipped in deionoized water, and mounted with DAPI
containing mounting media (Invitrogen). After drying
overnight, cells were visualized using the Bio-Rad Radi-
ance 2100 MP Rainbow confocal microscope. Fifty con-
jugates between NK and tumor targets were counted on
each coverslip. Conjugates were defined as an effector
(NK cell) and target (cancer cell line) in contact with
one another. Each conjugate was scored for polarization
of the activating synapse markers LFA-1 and F-actin or
CD2 and F-actin. Polarization was determined using two
criteria, both of which had to be met to be defined as a
synapse. These criteria were as follows: if greater than
70% of the fluorescence (of CD2 and F-actin or LFA-1
and F-actin) was noted to be at the interface between
target and effector cell, and if there was a noticeable
“flattening” of the membranes at the contact interface,
than the synapse was deemed an activating synapse. Per-
cent synapse formation was determined as: (number of
conjugates showing polarization of activating synapse
markers/total conjugates ×100).
Flow cytometry antibody staining
For flow cytometric analysis, cells were washed two
times in PBS containing 1% BSA by centrifugation at
300 ×g for 10 minutes at 4°C. Cells were labeled with
primary and secondary antibodies for 30 min on ice,
and washed with PBS containing 1% BSA in between
antibody staining and prior to flow cytometry. In the
DNAM-1-Fc and NKG2D-Fc binding experiments,
OVCAR-3, csMUC16
pos-OVC or csMUC16
neg-OVC
were blocked with Goat IgG (BD Biosciences) for 15
min., washed, and 15 μg/mL of either DNAM-Fc or
NKG2D-Fc (R&D Systems) was added for 30 min on
ice. Goat anti-human-Fc FITC (Jackson ImmunoRe-
search) was added for 30 min and washed. To determine
mucin and HLA class I expression cells were treated
with the primary antibodies. Where appropriate, cells
were stained with goat anti-mouse PE (1:100, Jackson
ImmunoResearch). Immediately before data acquisition
on an LSRII (Beckton Dickinson) flow cytometer, the
viability indicator PI or DAPI were added to each sam-
ple. Automatic compensation was applied. FlowJo soft-
ware (v. 4.6.1, TreeStar) was used for analysis of the raw
flow cytometry data, and comparison and statistical ana-
lysis (student t-test) of the data was done using Graph-
Pad Prism software (v. 4, GraphPad Software, Inc.).
Chromium-based cytotoxicity assays
csMUC16
neg-OVC, csMUC16
pos-OVC, or csMUC16
pos-
OVC-R were labeled with
51Cr in suspension. The tar-
gets were mixed with NK cells isolated from 4 healthy
donors in 96-well plates at different effector:target
ratios. After 4 h incubation,
51Cr released from the tar-
gets was measured and percent lysis was determined as
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Figure 9 Tumor cells surviving NKL challenge express higher
levels of csMUC16. A. csMUC16
pos-OVC cells not treated with NKL
or those surviving NKL treatment (csMUC16
pos-OVC-R) were
analyzed for csMUC16 expression by flow cytometry. Data is
representative of three independent experiments. B, csMUC16
pos-
OVC and csMUC16
pos-OVC-R were labeled with
51Cr. Cytotoxity
assays were performed by using NKL cells as effectors. After 4 h co-
incubation, released radioactivity was measured. Each bar is mean
of four independent assays.
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analysis (student t-test) of the data was done using
GraphPad Prism software (v. 4, GraphPad Software,
Inc.).
Cytotoxicity Assays of adherent csMUC16
neg-OVC and
csMUC16
pos-OVC cells
CellTracker Green (Invitrogen) labeled NKL cells were
added to wells of 6-well plates that contained confluent
csMUC16
neg-OVC or csMUC16
pos-OVC cells. After 24
h incubation, the media and the adherent cells were har-
vested using trypsin-EDTA, transferred to a tube,
stained with PI, and analyzed for percentage of live tar-
get cells by flow cytometry on a BD LSR-II instrument.
Comparison and statistical analysis (student t-test) of
the data was done using GraphPad Prism software (v. 4,
GraphPad Software, Inc.).
Lysis of adherent csMUC16
neg-OVC and csMUC16
pos-
OVC cells by NKL cells was also measured by counting
the number of surviving adherent tumor targets. These
experiments were set up similarly to the flow cytometry
based cytotoxicity assays except that NKL cells were not
stained. Following co-culture, the floating NKL cells and
dead tumor cells were removed by gentle washing and
the number of adherent (considered live) cells and colo-
nies were counted on an inverted microscope. The cell
counts from three independent experiments were pooled
and the averages (n = 15) were plotted. csMUC16
pos-
OVC cells that survived NKL challenge were further
cultured to confluence and re-challenged with NKL
cells. Tumor cells surviving this second NKL treatment
were harvested and analyzed by flow cytometry for
amount of csMUC16 expression.
Flow cytometry conjugate formation assay
Freshly isolated naïve NK cells were labeled with 0.5 μM
CellTracker Red (Invitrogen) for 25 minutes at 37°C in
5% CO2. Concurrently, csMUC16
neg-OVC and
csMUC16
pos-OVC cells were trypsinized, washed, and
dyed with 1.25 pM CellTracker Green (Invitrogen) in
the same conditions. After washing off excess dye with
PBS, cells were resuspended in PBS containing 1% BSA
solution. NK cells were placed in flow tubes with either
csMUC16
neg-OVC or csMUC16
pos-OVC cells at a 1:1
ratio and centrifuged for 2 minutes at 100 ×g. Tubes
were incubated for 25 minutes at room temperature,
and vortexing was avoided. Immediately before data
acquisition on an LSRII (Beckton Dickinson) flow cyt-
ometer, viability indicator DAPI (BD Biosciences) was
added to each sample. Comparison and statistical analy-
sis (student t-test) of the data was done using GraphPad
Prism software (v. 4, GraphPad Software, Inc.).
Plate adhesion assays
csMUC16
neg-OVC and csMUC16
pos-OVC were plated
at 100,000 cells/well of a 96-well plate and allowed to
grow for 48 hours to confluence. On the day of the
assay, NKL (natural killer leukemia) cells were dyed
with calcein AM (1 ug/mL, Invitrogen) in 1% PBS-BSA
for 30 min at 37°C, washed, and resuspended in media
containing FBS at a concentration of 50,000 or 100,000
NK cells/50 uL. Fifty μLo fd y e dN K L sw e r ea d d e dt o
each well containing the previously plated csMUC16
neg-
OVC or csMUC16
pos-OVC. The plate was centrifuged
at 400 ×g for 5 minutes and placed in the incubator for
25 minutes. The plate was washed gently with 1% PBS-
BSA three times to remove non-adherent cells and then
read using the Victor V-3 plate reader (Perkin Elmer).
Comparison and statistical analysis (student t-test) of
the data was done using GraphPad Prism software (v. 4,
GraphPad Software, Inc.).
Additional file 1: MUC16 is not detected in the lysates of
csMUC16
neg-OVC. 1. Lysates of OVCAR-3, csMUC16
pos-OVC, and
csMUC16
neg-OVC cells were analyzed by western blotting. MUC16 was
detected by using VK-8 (anti-CA125) as the primary antibody. Actin was
used as loading control.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-11-
S1.PPT]
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